Ulipristal: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 15, 2026

Ulipristal

Active ingredient · 2 therapeutic classes

Sold as CONTRELLA

GB MHRA

Drug class: Emergency Contraceptives
Availability: See label
Markets covered: 1
Products on record: 32

G03ADEmergency Contraceptives G03XBProgesterone Receptor Modulators

Overview

Ulipristal is an active pharmaceutical ingredient in the Emergency Contraceptives group (G03AD). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	32	May 15, 2026

GBUnited Kingdom· MHRA

32 products

Uses

GBOfficial regulatory label· revised May 15, 2026[1]

Emergency contraception within 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure.

How to take

Drug interactions

Known interactions involving Ulipristal. Select one for details. This list is informational and not a complete interaction checker.

Berotralstat Colchicine Edoxaban Venetoclax Abametapir Afatinib Aliskiren Ambrisentan Aminoglutethimide Amobarbital Apixaban Armodafinil Artesunate Betrixaban Bexarotene Bictegravir Binimetinib Bosentan Brentuximab Vedotin Butabarbital Butalbital Carbamazepine Ceritinib Cobimetinib Cyclosporine Daunorubicin Deferasirox Desogestrel Dienogest Digoxin Docetaxel Doxorubicin Drospirenone Duvelisib Efavirenz Epirubicin Erlotinib Etonogestrel Etoposide Etravirine Everolimus Felbamate Fexofenadine Fosphenytoin Fostamatinib Gilteritinib Griseofulvin Idarubicin Lapatinib Larotrectinib Lefamulin Lemborexant Lenalidomide Levonorgestrel Lonafarnib Loperamide Lorlatinib Lusutrombopag Maraviroc Medroxyprogesterone Mephobarbital Mitoxantrone Modafinil Naldemedine Nevirapine Nilotinib Norelgestromin Norethindrone Norgestimate Norgestrel Oxcarbazepine Paclitaxel Pentobarbital Pexidartinib Phenobarbital Phenylbutazone Phenytoin Primidone Quinidine Ranolazine Relugolix Ribociclib Rifabutin Rifampin Rifapentine Rifaximin Riociguat Ripretinib Ritonavir Rivaroxaban Romidepsin Rucaparib Rufinamide Secobarbital Selpercatinib Silodosin Sirolimus Somapacitan Somatrem Somatropin Sulfinpyrazone Talazoparib Telotristat Ethyl Terfenadine Ticagrelor Tipranavir Tolvaptan Topiramate Topotecan Troglitazone Tucatinib Ubrogepant Vinblastine Vincristine Vinorelbine Amiodarone Aprepitant Atazanavir Clarithromycin Clotrimazole Conivaptan Dalfopristin Danazol Darunavir Delavirdine Diltiazem Dronedarone Erythromycin Fidaxomicin Fluconazole Fluvoxamine Fosamprenavir Fosaprepitant Grepafloxacin Imatinib Indacaterol Indinavir Isoniazid Itraconazole Ketoconazole Miconazole Naloxegol Nefazodone Nelfinavir Nifedipine Posaconazole Prucalopride Saquinavir Telithromycin Troleandomycin Verapamil Voriconazole Zafirlukast

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL044161762 · revised May 15, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised May 15, 2026[1]

Summary of the safety profile The most commonly reported adverse reactions were headache, nausea, abdominal pain and dysmenorrhea. Safety of ulipristal acetate has been evaluated in 4,718 women during the clinical development program.
Tabulated list of adverse reactions The adverse reactions reported in the phase III program of 2,637 women are provided in the table below. Adverse reactions listed below are classified according to frequency and system organ class using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the available data).
2). Post-marketing experience: the adverse reactions spontaneously reported in post-marketing experience were similar in nature and frequency to the safety profile described during the phase III program. 5% had a delay of more than 7 days beyond the anticipated onset of menses.
The delay was greater than 20 days in 4 % of the women. 4 days. 2%), this bleeding was reported as spotting. 4% reported heavy intermenstrual bleeding. In the phase III studies, 82 women entered a study more than once and therefore received more than one dose of ulipristal acetate (73 women enrolled twice and 9 enrolled three times).
There were no safety differences in these subjects in terms of incidence and severity of adverse events, change in duration or volume of menses or incidence of intermenstrual bleeding. Reporting of suspected adverse reactions Reporting of suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store.

GBOfficial regulatory label· Warnings and precautions· revised May 15, 2026[1]

Ulipristal Sandoz Film-coated Tablets is for occasional use only. It should in no instance replace a regular contraceptive method. In any case, women should be advised to adopt a regular method of contraception. Ulipristal acetate is not intended for use during pregnancy and should not be taken by any woman suspected or known to be pregnant.
6). Ulipristal acetate does not prevent pregnancy in every case In case the next menstrual period is more than 7 days late, if the menstrual period is abnormal in character or if there are symptoms suggestive of pregnancy or in case of doubt, a pregnancy test should be performed.
As with any pregnancy, the possibility of an ectopic pregnancy should be considered. It is important to know that the occurrence of uterine bleeding does not rule out ectopic pregnancy. 6). 1). If ovulation has already occurred, it is no longer effective.
The timing of ovulation cannot be predicted and therefore the tablet should be taken as soon as possible after unprotected intercourse. No data are available on the efficacy of ulipristal acetate when taken more than 120 hours (5 days) after unprotected intercourse.
1). In all women, emergency contraception should be taken as soon as possible after unprotected intercourse, regardless of the woman’s body weight or BMI. After the tablet intake menstrual periods can sometimes occur a few days earlier or later than expected.
In approximately 7% of the women, menstrual periods occurred more than 7 days earlier than expected. 5% of the women a delay of more than 7 days occurred, and in 4% the delay was greater than 20 days. 5). Contraception after ulipristal acetate intake Ulipristal acetate is an emergency contraceptive that decreases pregnancy risk after unprotected intercourse but does not confer contraceptive protection for subsequent acts of intercourse.
Therefore, after using emergency contraception, women should be advised to use a reliable barrier method until her next menstrual period. 5). Therefore, if a woman wishes to start or continue using hormonal contraception, she can do so after using ulipristal acetate, however, she should be advised to use a reliable barrier method until the next menstrual period.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drug interactions

Drugs in the same class

Sources & citations